

TRISTEL plc
("Tristel" or the "Company")

Updated US guidelines for high level disinfection

American Institute of Ultrasound in Medicine expands U.S. Guidelines to include chlorine dioxide for high level disinfection of ultrasound probe

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, notes with satisfaction the publication by the American Institute of Ultrasound in Medicine ("AIUM") regarding its expanded guidelines on the handling and reprocessing of ultrasound probes in healthcare environments. For the first time, the AIUM guidelines include chlorine dioxide as an accepted option for high-level disinfection ("HLD").

Chlorine dioxide for ultrasound probe disinfection is branded as Tristel's HLD foam product, Tristel ULT™, in the United States ("US"). Tristel ULT™ is manufactured and distributed by Parker Laboratories under an exclusive partnership agreement with Tristel, and is the only FDA-cleared chlorine dioxide foam disinfectant for ultrasound probes available in the US market.

Matt Sassone, Chief Executive Officer of Tristel plc said: *"We are delighted to see AIUM's decision to include chlorine dioxide as an approved method for high-level disinfection for ultrasound instruments. Together with the inclusion last year of chlorine dioxide foam in the American national standard on chemical sterilisation and high-level disinfection (ANSI/AAMI ST58:2024) - which acknowledges this modality as a valid HLD option - this marks a significant milestone for the U.S. market.*

"Tristel ULT™ has been approved for use in more than 35 countries since 2008 and this update underscores the importance of our technology in highly sterilised care environments where consistency and compliance are of critical importance.

"With the AIUM guideline update and the enhanced national standard, we believe the conditions are well-aligned for accelerated adoption of Tristel ULT™ in the US ultrasound market - supporting frontline clinicians, infection-prevention teams and hospital administrators alike."

For the full announcement on the revised guidelines from Tristel's partner, Parker Laboratories, please see [here](#).

For further information please contact:

Tristel plc

Matt Sassone, Chief Executive Officer
Anna Wasyli, Chief Financial Officer

Via Walbrook PR

www.investors.tristel.com

Walbrook PR Ltd

Paul McManus / Lianne Applegarth / Anna Dunphy

Tel: 020 7933 8780 or tristel@walbrookpr.com

Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

Cavendish Capital Markets Ltd

Geoff Nash / Callum Davidson / Trisyia Jamaludin (Corporate Finance)
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

Tel: 020 7220 0500



About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO₂) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the [Tristel](#) brand, and under the [Cache](#) brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets double digit revenue growth annually and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: <https://tristel.com>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.rs.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCBJBMTMTTBLA